{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T22:12:58Z","timestamp":1778623978862,"version":"3.51.4"},"reference-count":57,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Antitumor immunity is augmented by cytotoxic lymphodepletion therapies. Adoptively transferred naive and effector T cells proliferate extensively and show enhanced antitumor effects in lymphopenic recipients. Although the impact of lymphodepletion on transferred donor T cells has been well evaluated, its influence on recipient T cells is largely unknown. The current study demonstrates that both regulatory T cells (Tregs) and effector CD8+ T cells from lymphopenic recipients play critical roles in the development of antitumor immunity after lymphodepletion. Cyclophosphamide (CPA) treatment depleted lymphocytes more efficiently than other cytotoxic agents; however, the percentage of CD4+CD25+ Foxp3+ Tregs was significantly increased in CPA-treated lymphopenic mice. Depletion of these chemoresistant Tregs following CPA treatment and transfer of naive CD4+ T cells augmented the antitumor immunity and significantly suppressed tumor progression. Further analyses revealed that recipient CD8+ T cells were responsible for this augmentation. Using Rag2\u2212\/\u2212 mice or depletion of recipient CD8+ T cells after CPA treatment abrogated the augmentation of antitumor effects in CPA-treated reconstituted mice. The transfer of donor CD4+ T cells enhanced the proliferation of CD8+ T cells and the priming of tumor-specific CD8+ T cells originating from the lymphopenic recipients. These results highlight the importance of the recipient cells surviving cytotoxic regimens in cancer immunotherapies.<\/jats:p>","DOI":"10.4049\/jimmunol.1401468","type":"journal-article","created":{"date-parts":[[2015,6,4]],"date-time":"2015-06-04T11:15:25Z","timestamp":1433416525000},"page":"726-735","source":"Crossref","is-referenced-by-count":27,"title":["Critical Roles of Chemoresistant Effector and Regulatory T Cells in Antitumor Immunity after Lymphodepleting Chemotherapy"],"prefix":"10.1093","volume":"195","author":[{"given":"Yu","family":"Saida","sequence":"first","affiliation":[{"name":"Department of Medicine (II), Niigata University Medical and Dental Hospital , Niigata City, Niigata 951-8520 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Bioscience Medical Research Center, Niigata University Medical and Dental Hospital , Niigata City, Niigata 951-8520 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Medicine (II), Niigata University Medical and Dental Hospital , Niigata City, Niigata 951-8520 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junko","family":"Baba","sequence":"additional","affiliation":[{"name":"Department of Medicine (II), Niigata University Medical and Dental Hospital , Niigata City, Niigata 951-8520 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ko","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Medicine (II), Niigata University Medical and Dental Hospital , Niigata City, Niigata 951-8520 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Shoji","sequence":"additional","affiliation":[{"name":"Department of Medicine (II), Niigata University Medical and Dental Hospital , Niigata City, Niigata 951-8520 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsue","family":"Igarashi","sequence":"additional","affiliation":[{"name":"Department of Medicine (II), Niigata University Medical and Dental Hospital , Niigata City, Niigata 951-8520 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rie","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Medicine (II), Niigata University Medical and Dental Hospital , Niigata City, Niigata 951-8520 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Okajima","sequence":"additional","affiliation":[{"name":"Department of Medicine (II), Niigata University Medical and Dental Hospital , Niigata City, Niigata 951-8520 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Koshio","sequence":"additional","affiliation":[{"name":"Department of Medicine (II), Niigata University Medical and Dental Hospital , Niigata City, Niigata 951-8520 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Ichikawa","sequence":"additional","affiliation":[{"name":"Department of Medicine (II), Niigata University Medical and Dental Hospital , Niigata City, Niigata 951-8520 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Nozaki","sequence":"additional","affiliation":[{"name":"Department of Medicine (II), Niigata University Medical and Dental Hospital , Niigata City, Niigata 951-8520 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Medicine (II), Niigata University Medical and Dental Hospital , Niigata City, Niigata 951-8520 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Koya","sequence":"additional","affiliation":[{"name":"Department of Medicine (II), Niigata University Medical and Dental Hospital , Niigata City, Niigata 951-8520 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Miura","sequence":"additional","affiliation":[{"name":"Department of Medicine (II), Niigata University Medical and Dental Hospital , Niigata City, Niigata 951-8520 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junta","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Medicine (II), Niigata University Medical and Dental Hospital , Niigata City, Niigata 951-8520 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kagamu","sequence":"additional","affiliation":[{"name":"Department of Medicine (II), Niigata University Medical and Dental Hospital , Niigata City, Niigata 951-8520 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirohisa","family":"Yoshizawa","sequence":"additional","affiliation":[{"name":"Bioscience Medical Research Center, Niigata University Medical and Dental Hospital , Niigata City, Niigata 951-8520 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koh","family":"Nakata","sequence":"additional","affiliation":[{"name":"Bioscience Medical Research Center, Niigata University Medical and Dental Hospital , Niigata City, Niigata 951-8520 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiei","family":"Narita","sequence":"additional","affiliation":[{"name":"Department of Medicine (II), Niigata University Medical and Dental Hospital , Niigata City, Niigata 951-8520 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2015,7,15]]},"reference":[{"key":"2025030703443908300_r1","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1084\/jem.155.4.1063","article-title":"Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells","volume":"155","author":"North","year":"1982","journal-title":"J. Exp. Med."},{"key":"2025030703443908300_r2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/BF00205425","article-title":"Gamma-irradiation facilitates the expression of adoptive immunity against established tumors by eliminating suppressor T cells","volume":"16","author":"North","year":"1984","journal-title":"Cancer Immunol. Immunother."},{"key":"2025030703443908300_r3","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nri3191","article-title":"Adoptive immunotherapy for cancer: harnessing the T cell response","volume":"12","author":"Restifo","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"2025030703443908300_r4","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrclinonc.2011.116","article-title":"Cell transfer immunotherapy for metastatic solid cancer\u2014what clinicians need to know","volume":"8","author":"Rosenberg","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2025030703443908300_r5","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1172\/JCI0215175","article-title":"T cell homeostatic proliferation elicits effective antitumor autoimmunity","volume":"110","author":"Dummer","year":"2002","journal-title":"J. Clin. Invest."},{"key":"2025030703443908300_r6","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1084\/jem.192.4.557","article-title":"Naive T cells transiently acquire a memory-like phenotype during homeostasis-driven proliferation","volume":"192","author":"Goldrath","year":"2000","journal-title":"J. Exp. Med."},{"key":"2025030703443908300_r7","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0092-8674(04)00335-6","article-title":"Homeostatic expansion of T cells during immune insufficiency generates autoimmunity","volume":"117","author":"King","year":"2004","journal-title":"Cell"},{"key":"2025030703443908300_r8","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1002\/eji.200324034","article-title":"Anti-tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution","volume":"33","author":"Ma","year":"2003","journal-title":"Eur. J. Immunol."},{"key":"2025030703443908300_r9","doi-asserted-by":"crossref","first-page":"729","DOI":"10.4049\/jimmunol.147.2.729","article-title":"Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2","volume":"147","author":"Yoshizawa","year":"1991","journal-title":"J. Immunol."},{"key":"2025030703443908300_r10","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1182\/blood-2006-09-045245","article-title":"Adoptive transfer of tumor-primed, in vitro-activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response","volume":"109","author":"Wang","year":"2007","journal-title":"Blood"},{"key":"2025030703443908300_r11","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1182\/blood-2012-02-411124","article-title":"Depletion of radio-resistant regulatory T cells enhances antitumor immunity during recovery from lymphopenia","volume":"120","author":"Baba","year":"2012","journal-title":"Blood"},{"key":"2025030703443908300_r12","first-page":"1657","article-title":"Adoptive immunotherapy of newly induced murine sarcomas","volume":"45","author":"Shu","year":"1985","journal-title":"Cancer Res."},{"key":"2025030703443908300_r13","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.4049\/jimmunol.175.8.5058","article-title":"Both regulatory T cells and antitumor effector T cells are primed in the same draining lymph nodes during tumor progression","volume":"175","author":"Hiura","year":"2005","journal-title":"J. Immunol."},{"key":"2025030703443908300_r14","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/0008-8749(91)90318-6","article-title":"Activation by anti-CD3 of tumor-draining lymph node cells for specific adoptive immunotherapy","volume":"134","author":"Yoshizawa","year":"1991","journal-title":"Cell. Immunol."},{"key":"2025030703443908300_r15","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.4049\/jimmunol.181.5.3291","article-title":"Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes","volume":"181","author":"Watanabe","year":"2008","journal-title":"J. Immunol."},{"key":"2025030703443908300_r16","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1172\/JCI30414","article-title":"Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells","volume":"117","author":"Wrzesinski","year":"2007","journal-title":"J. Clin. Invest."},{"key":"2025030703443908300_r17","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1200\/JCO.2008.16.5449","article-title":"Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens","volume":"26","author":"Dudley","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"2025030703443908300_r18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CJI.0b013e3181b88ffc","article-title":"Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells","volume":"33","author":"Wrzesinski","year":"2010","journal-title":"J. Immunother."},{"key":"2025030703443908300_r19","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/978-0-387-69219-7_17","article-title":"Significance of regional draining lymph nodes in the development of tumor immunity: implications for cancer immunotherapy","volume":"135","author":"Zheng","year":"2007","journal-title":"Cancer Treat. Res."},{"key":"2025030703443908300_r20","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.4049\/jimmunol.160.7.3444","article-title":"Purification of L-selectin(low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes","volume":"160","author":"Kagamu","year":"1998","journal-title":"J. Immunol."},{"key":"2025030703443908300_r21","first-page":"1129","article-title":"Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3\/interleukin 2-activated tumor-draining lymph node cells","volume":"52","author":"Yoshizawa","year":"1992","journal-title":"Cancer Res."},{"key":"2025030703443908300_r22","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1158\/0008-5472.CAN-05-4128","article-title":"Tumor-driven evolution of immunosuppressive networks during malignant progression","volume":"66","author":"Kim","year":"2006","journal-title":"Cancer Res."},{"key":"2025030703443908300_r23","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1146\/annurev.immunol.25.022106.141609","article-title":"Immunosuppressive strategies that are mediated by tumor cells","volume":"25","author":"Rabinovich","year":"2007","journal-title":"Annu. Rev. Immunol."},{"key":"2025030703443908300_r24","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/nri1434","article-title":"TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response","volume":"4","author":"Baniyash","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"2025030703443908300_r25","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.smim.2007.10.004","article-title":"T cell immune reconstitution following lymphodepletion","volume":"19","author":"Williams","year":"2007","journal-title":"Semin. Immunol."},{"key":"2025030703443908300_r26","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3626","article-title":"The secret ally: immunostimulation by anticancer drugs","volume":"11","author":"Galluzzi","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"2025030703443908300_r27","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00262-012-1388-0","article-title":"Chemoimmunotherapy: reengineering tumor immunity","volume":"62","author":"Chen","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"2025030703443908300_r28","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1084\/jem.20050732","article-title":"Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells","volume":"202","author":"Gattinoni","year":"2005","journal-title":"J. Exp. Med."},{"key":"2025030703443908300_r29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.it.2004.12.003","article-title":"Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy","volume":"26","author":"Klebanoff","year":"2005","journal-title":"Trends Immunol."},{"key":"2025030703443908300_r30","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.coi.2009.02.004","article-title":"Adoptive immunotherapy of cancer using CD4(+) T cells","volume":"21","author":"Muranski","year":"2009","journal-title":"Curr. Opin. Immunol."},{"key":"2025030703443908300_r31","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3389\/fimmu.2014.00174","article-title":"How do CD4(+) T cells detect and eliminate tumor cells that either lack or express MHC class II molecules?","volume":"5","author":"Haabeth","year":"2014","journal-title":"Front. Immunol."},{"key":"2025030703443908300_r32","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2217\/imt.11.83","article-title":"Tumor-reactive CD4+ T cells: plasticity beyond helper and regulatory activities","volume":"3","author":"Quezada","year":"2011","journal-title":"Immunotherapy"},{"key":"2025030703443908300_r33","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1084\/jem.20091921","article-title":"Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma","volume":"207","author":"Xie","year":"2010","journal-title":"J. Exp. Med."},{"key":"2025030703443908300_r34","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S0952-7915(98)80228-8","article-title":"The role of CD4+ T cell responses in antitumor immunity","volume":"10","author":"Pardoll","year":"1998","journal-title":"Curr. Opin. Immunol."},{"key":"2025030703443908300_r35","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.4049\/jimmunol.174.5.2591","article-title":"CD8+ T cell immunity against a tumor\/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells","volume":"174","author":"Antony","year":"2005","journal-title":"J. Immunol."},{"key":"2025030703443908300_r36","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/eji.200324181","article-title":"CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative","volume":"34","author":"Ghiringhelli","year":"2004","journal-title":"Eur. J. Immunol."},{"key":"2025030703443908300_r37","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1084\/jem.20042167","article-title":"Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response","volume":"201","author":"Ercolini","year":"2005","journal-title":"J. Exp. Med."},{"key":"2025030703443908300_r38","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients","volume":"56","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"2025030703443908300_r39","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1158\/0008-5472.CAN-08-4102","article-title":"Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model","volume":"69","author":"Wada","year":"2009","journal-title":"Cancer Res."},{"key":"2025030703443908300_r40","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00262-011-1106-3","article-title":"Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome","volume":"61","author":"Ge","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"2025030703443908300_r41","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/nm.2883","article-title":"Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival","volume":"18","author":"Walter","year":"2012","journal-title":"Nat. Med."},{"key":"2025030703443908300_r42","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00262-012-1343-0","article-title":"Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo","volume":"62","author":"Tongu","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"2025030703443908300_r43","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/287551a0","article-title":"Induction of experimental allergic encephalomyelitis in genetically resistant strains of mice","volume":"287","author":"Lando","year":"1980","journal-title":"Nature"},{"key":"2025030703443908300_r44","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jdermsci.2005.02.002","article-title":"Cyclophosphamide decreases the number, percentage and the function of CD25+ CD4+ regulatory T cells, which suppress induction of contact hypersensitivity","volume":"39","author":"Ikezawa","year":"2005","journal-title":"J. Dermatol. Sci."},{"key":"2025030703443908300_r45","doi-asserted-by":"crossref","first-page":"6603","DOI":"10.4049\/jimmunol.177.10.6603","article-title":"Cyclophosphamide-induced type-1 diabetes in the NOD mouse is associated with a reduction of CD4+CD25+Foxp3+ regulatory T cells","volume":"177","author":"Brode","year":"2006","journal-title":"J. Immunol."},{"key":"2025030703443908300_r46","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jaci.2005.10.042","article-title":"Cyclophosphamide augments inflammation by reducing immunosuppression in a mouse model of allergic airway disease","volume":"117","author":"Su","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"2025030703443908300_r47","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1615\/CritRevImmunol.v28.i2.20","article-title":"Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide","volume":"28","author":"Brode","year":"2008","journal-title":"Crit. Rev. Immunol."},{"key":"2025030703443908300_r48","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1097\/MPA.0b013e3181da9037","article-title":"An immunohistochemical study on the distribution and frequency of T regulatory cells in pancreatic islets of NOD mice during various stages of spontaneous and cyclophosphamide-accelerated diabetes","volume":"39","author":"Kaur","year":"2010","journal-title":"Pancreas"},{"key":"2025030703443908300_r49","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1084\/jem.20030686","article-title":"Continuous activation of autoreactive CD4+ CD25+ regulatory T cells in the steady state","volume":"198","author":"Fisson","year":"2003","journal-title":"J. Exp. Med."},{"key":"2025030703443908300_r50","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.4049\/jimmunol.181.3.1806","article-title":"CTLA4 expression is an indicator and regulator of steady-state CD4+ FoxP3+ T cell homeostasis","volume":"181","author":"Tang","year":"2008","journal-title":"J. Immunol."},{"key":"2025030703443908300_r51","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nri2216","article-title":"Immunological aspects of cancer chemotherapy","volume":"8","author":"Zitvogel","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"2025030703443908300_r52","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1158\/0008-5472.CAN-11-3912","article-title":"Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective","volume":"72","author":"Le","year":"2012","journal-title":"Cancer Res."},{"key":"2025030703443908300_r53","doi-asserted-by":"crossref","first-page":"4850","DOI":"10.1158\/0008-5472.CAN-10-0283","article-title":"Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels","volume":"70","author":"Zhao","year":"2010","journal-title":"Cancer Res."},{"key":"2025030703443908300_r54","first-page":"8408","article-title":"Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model","volume":"63","author":"Hermans","year":"2003","journal-title":"Cancer Res."},{"key":"2025030703443908300_r55","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.4049\/jimmunol.176.5.2722","article-title":"Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines","volume":"176","author":"Taieb","year":"2006","journal-title":"J. Immunol."},{"key":"2025030703443908300_r56","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1200\/JCO.2005.00.240","article-title":"Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma","volume":"23","author":"Dudley","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"2025030703443908300_r57","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1182\/blood-2011-10-387969","article-title":"CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results","volume":"119","author":"Till","year":"2012","journal-title":"Blood"}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/195\/2\/726\/61501804\/1401468.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/195\/2\/726\/61501804\/1401468.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T03:45:41Z","timestamp":1741319141000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/195\/2\/726\/7961083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,7,15]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.1401468","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,7]]},"published":{"date-parts":[[2015,7]]}}}